Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
58.5M
-
Shares change
-
+7.32M
-
Total reported value, excl. options
-
$563M
-
Value change
-
+$83.6M
-
Put/Call ratio
-
0.98
-
Number of buys
-
63
-
Number of sells
-
-45
-
Price
-
$9.62
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q3 2019
135 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q3 2019.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 58.5M shares
of 126M outstanding shares and own 46.24% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (6.05M shares), Consonance Capital Management LP (5.84M shares), WELLINGTON MANAGEMENT GROUP LLP (5.76M shares), Palo Alto Investors LP (4.84M shares), BlackRock Inc. (4.7M shares), STATE STREET CORP (3.15M shares), VANGUARD GROUP INC (2.74M shares), FRONTIER CAPITAL MANAGEMENT CO LLC (1.78M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.7M shares), and CITADEL ADVISORS LLC (1.53M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.